|
Sep 18
|
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
|
|
Aug 8
|
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
|
|
Jul 29
|
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
|
|
May 21
|
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
|
|
May 15
|
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
|
|
Apr 18
|
BiomX Announces the Appointment of Susan Blum to its Board of Directors
|
|
Mar 27
|
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
|
|
Nov 30
|
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
|
|
Nov 29
|
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
|
|
Oct 18
|
BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
|
|
Aug 9
|
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
|